Investor Presentaiton

Matching modality to mechanism: Leveraging expertise across multiple modalities Small molecule chemistry Biotherapeutics Allosteric inhibitors Nu Viral RNA Al-assisted screening ProbodyⓇ Therapeutic Immune cell engagers Active site inhibitors Nucleic acid therapies Lentivirus and AAV gene therapy Glycosylation -00120 arw Glycoprene Complex Proces of Host Cel Lipid Membrane Mairie Protein Targeted Protein Degradation Molecular glue Target protein Molecular glue molecule Hetero- bifunctional Target protein ADC degrader megrine Preverse Trip Pre 3 E3 ligase E3 ligase Established Ill Bristol Myers Squibb™ Emerging ⚫ Cysteine residue • Drug-Linker CELMOD LDD CELMOD ADC Discuss today Bi-specifics ADCs Cell Therapy Autologous Single CAR binder Next-generation Multiple other KO/KI TCR ΚΟ MHC-I Dual CAR binder KO MHC-II KO Dual CAR binder Allogeneic, iPSC-derived Not for Product Promotional Use 28

View entire presentation